Core Viewpoint - Dr. Markus Braun has resigned as Executive Director and Chief Financial Officer of 德视佳 (01846.HK) due to personal career development plans, effective September 14, 2025 [1] Group 1 - The company announced the resignation of Dr. Markus Braun from his positions, including as the authorized representative under listing rules and as the legal representative for company regulations [1] - Mr. Marcus Huascar Bracklo has been promoted from Non-Executive Director to Executive Director and appointed as Chief Financial Officer, effective September 14, 2025 [1]

Hans Helmuth Hennig先生 Katherine Rong Xin女士 Philip Duncan Wright先生 本公司設立三個董事委員會。下表載列各董事於該等委員會擔任的職務的資料， 由2025年9月14日起生效。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 董事名單與其角色和職能 德視佳國際眼科有限公司（「本公司」）董事（「董事」）會（「董事會」）成員載列如 下，由2025年9月14日起生效： 執行董事 Jørn Slot Jørgensen醫生 （主席） Jannik Jonas Slot Jørgensen先生 Dan Zoltan Reinstein教授 Marcus Huascar Bracklo先生 獨立非執行董事 | 董事委員會 | | | | | --- | --- | --- | --- | | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | Jørn Slot Jørgensen醫生 | | M | C | | Jannik Jonas ...

Group 1 - Dr. Markus Braun has resigned as Executive Director and Chief Financial Officer of 德视佳 (01846) due to personal career development plans, effective from September 14, 2025 [1] - Mr. Marcus Huascar Bracklo has been appointed as Executive Director and Chief Financial Officer, effective from September 14, 2025 [1] - Following the appointment, Mr. Bracklo will no longer be a member of the Audit Committee, and independent non-executive director Ms. Katherine Rong Xin will join the Audit Committee [1] Group 2 - The Audit Committee will consist of Mr. Philip Duncan Wright (Chairman), Mr. Hans Helmuth Hennig, and Ms. Xin, effective from September 14, 2025 [1] - Mr. Bracklo will also serve as the authorized representative under the Listing Rules and the Companies Ordinance, filling Dr. Braun's vacancy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） (1) 執行董事兼首席財務官辭任； (2) 執行董事調任及委任首席財務官； (3) 審核委員會組成之變更；及 EuroEyes International Eye Clinic Limited (4) 上市規則授權代表及公司條例授權代表及 法律程序文件代理人之變更 (1) 執行董事兼首席財務官辭任 德視佳國際眼科有限公司（「本公司」，連同其附屬公司，統稱為「本集團」）董 事（「董事」）會（「董事會」）宣佈，因彼本身的職業發展規劃，Markus Braun博 士（「Braun博士」）已提出辭任本公司執行董事兼首席財務官（「首席財務官」） 並將不再擔任(i)香港聯合交易所有限公司證券上市規則（「上市規則」）第3.05 條項下之本公司授權代表（「上市規則授權代表」）；及(ii)根據香港法例第622 章公司條例第16部代表本公司於香 ...

德视佳(01846.HK)拟8月28日举行董事会会议以审批中期业绩 德视佳(01846.HK)获Jørgensen Jannik Jonas Slot增持11.8万股 格隆汇8月15日丨德视佳(01846.HK)公告，公司将于2025年8月28日(星期四)举行董事会会议，以(其中包 括)(i)审阅及批准公司及其附属公司截至2025年6月30日止6个月中期业绩及其刊发；(ii)考虑建议派付中 期股息(如适用)；及(iii)处理任何其他事务。 相关事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 於本公告日期，董事會包括執行董事Jørn Slot Jørgensen醫生、Markus Braun 博士、Jannik Jonas Slot Jørgensen先生及Dan Zoltan Reinstein教授；非執行董 事Marcus Huascar Bracklo先生；獨立非執行董事Hans Helmuth Hennig先生、 Katherine Rong Xin女士及Philip Duncan Wright先生。 德視佳國際眼科有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本 公司將於2025年8月28日（星期四）舉行董事會會議，以（其中包括）(i)審閱及批准 本公司及其附屬公司截至2025年6月30日止六個月之中期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊股 ...

Financial Performance - Revenue for 2024 reached HKD 715,682,000, a slight increase from HKD 714,289,000 in 2023[7] - Gross profit decreased to HKD 286,593,000, resulting in a gross margin of 40.0%, down from 47.0% in the previous year[7] - Net profit for the year was HKD 84,359,000, reflecting a net profit margin of 11.8%, compared to 18.7% in 2023[7] - Adjusted net profit after tax was HKD 100,334,000, with an adjusted net profit margin of 14.0%[7] - The company reported an adjusted profit attributable to owners of HKD 98,260,000, down from HKD 139,705,000 in 2023[7] - EBITDA fell by 18.8% to HKD 228.0 million, with adjusted EBITDA down 16.8% to HKD 240.5 million, reflecting the impact of new clinic costs[19] - Net profit attributable to equity holders decreased by 37.3% to HKD 82.3 million, largely due to additional costs from new clinics[19] - The total revenue for the fiscal year reached HKD 715.7 million, a year-on-year increase of 0.2%, primarily driven by strong growth in presbyopia cataract surgeries in Germany, China, and the UK[32] Revenue Breakdown - The company achieved a record revenue of HKD 715.7 million for the fiscal year 2024, up from HKD 714.3 million in 2023, with contributions from Germany, China, Denmark, and the UK being approximately HKD 385.2 million, HKD 145.5 million, HKD 71.6 million, and HKD 113.4 million respectively[13][14][18]. - Revenue from presbyopia treatment increased to HKD 390.8 million, representing a 5% growth compared to the previous year, and accounted for 54.6% of total revenue[14][17][18]. - In Germany, total revenue grew by 1% to HKD 385.2 million, driven by a 2.6% increase in revenue from lens replacement surgeries[14][20]. - The UK revenue rose by 12% to HKD 113.4 million, supported by the opening of the flagship Laser Eye Clinic in Knightsbridge, which focused on presbyopia treatment[14][20]. - In China, despite a significant drop in consumer confidence, revenue from lens replacement surgeries increased by 1% to HKD 145.5 million, offsetting declines in other treatment areas[15][19]. Cost and Expenses - The company's gross profit decreased by 14.6% to HKD 286.6 million, primarily due to the fixed costs of new clinics and inflation-related salary increases[18][19]. - Total cost of revenue increased by 13.3% to HKD 429.1 million in 2024, primarily due to higher employee benefits and depreciation of property, plant, and equipment[35]. - Selling expenses rose by 10.8% to approximately HKD 80.8 million, representing 11.3% of total revenue, compared to 10.2% in the previous year[37]. - Administrative expenses increased by 29.6% to approximately HKD 115.7 million, accounting for 16.2% of total revenue, up from 12.5% in 2023[39]. Strategic Focus and Expansion - The company aims to focus on profitable treatments, particularly for myopia and presbyopia, while controlling costs to achieve rapid breakeven[12]. - The company plans to enhance its focus on presbyopia treatments through lens replacement surgeries[12]. - The company plans to continue its expansion strategy in Europe and Asia, targeting new markets through acquisitions by 2025[15][17]. - The company opened four new clinics during the fiscal year, which contributed an impact of HKD 43.8 million to net profit[19]. - New flagship clinics in Hong Kong and London have exceeded expectations, with emerging clinics in mainland China also performing well[29]. Management and Governance - The company has a strong management team with extensive experience in ophthalmology and financial management, enhancing operational oversight in various regions[88][91]. - The company emphasizes the importance of its management team, noting that the loss of key personnel could impact operations and incur additional costs[103]. - The company has established a compensation committee to review the remuneration policies for directors and senior management based on performance and market practices[125]. Shareholder Information - The company reported a proposed final dividend of HKD 0.0297 per ordinary share, totaling approximately HKD 9,524,968, subject to approval at the upcoming annual general meeting[97]. - As of December 31, 2024, the distributable reserves available for shareholders amount to HKD 981,352,000, down from HKD 1,042,276,000 in 2023[118]. - The company’s dividend policy will be reviewed periodically by the board, considering factors such as financial performance and capital needs[100]. Risks and Compliance - The company faces risks related to economic instability, which could affect demand for its vision correction services[104]. - The company’s operations are compliant with relevant laws and regulations in Germany, Denmark, the UK, China, the Cayman Islands, and Hong Kong[110]. - The company has not been aware of any serious violations of employee-related laws and regulations that would significantly impact its operations[124]. Environmental and Social Responsibility - The company has implemented various environmental protection measures to reduce energy consumption, supported by its employees[108]. - The company has been involved in humanitarian efforts related to cataract surgery in countries such as China, Myanmar, and Nepal[89]. - The company is committed to delivering high-quality services and actively seeks customer feedback through patient surveys[113].

Financial Performance - Total revenue for the year ended December 31, 2024, was HKD 715,682,000, a slight increase of 0.2% compared to HKD 714,289,000 in 2023[3] - Gross profit decreased by 14.6% to HKD 286,593,000 from HKD 335,521,000 in the previous year[3] - Adjusted gross profit for 2024 was HKD 298,506,000, down 12.1% from HKD 339,412,000 in 2023[3] - Net profit for the year fell by 36.7% to HKD 84,359,000 compared to HKD 133,254,000 in 2023[3] - Adjusted net profit after tax decreased by 29.2% to HKD 100,334,000 from HKD 141,717,000 in the previous year[3] - Operating profit for the year was HKD 115,779,000, down from HKD 193,514,000 in 2023[7] - Basic earnings per share for 2024 were HKD 24.929, compared to HKD 39.544 in 2023[8] - Total comprehensive income for the year was HKD 22,354,000, a decrease from HKD 165,848,000 in 2023[8] - EBITDA for 2024 was HKD 227,993,000, compared to HKD 280,864,000 in 2023, reflecting a decline of 18.8%[24] - The net profit for the year ended December 31, 2024, was HKD 84,359,000, down from HKD 133,254,000 in 2023, a decrease of 36.7%[24] - Basic earnings per share decreased to HKD 24.929 in 2024 from HKD 39.544 in 2023, reflecting a decline of approximately 37%[37] Revenue Breakdown - Revenue from vision correction services for 2024 was HKD 710,875,000, slightly up from HKD 707,897,000 in 2023, showing an increase of 0.3%[25] - The revenue from training services decreased to HKD 3,613,000 in 2024 from HKD 5,407,000 in 2023, a decline of 33.1%[25] - The revenue from the German segment for 2024 was HKD 395,996,000, an increase from HKD 386,162,000 in 2023, representing a growth of 2.1%[24] - The Chinese segment reported revenue of HKD 145,468,000 in 2024, slightly up from HKD 144,316,000 in 2023, an increase of 0.8%[24] - The UK segment's revenue increased to HKD 113,431,000 in 2024 from HKD 101,486,000 in 2023, reflecting a growth of 11.8%[24] - The Danish segment's revenue decreased to HKD 71,638,000 in 2024 from HKD 87,919,000 in 2023, a decline of 18.5%[24] - Revenue from lens replacement surgeries reached HKD 390.8 million, marking a 5.1% increase from the previous year[51] - The proportion of revenue from lens replacement surgeries increased from 52.8% in 2023 to 54.6% in 2024[51] - Total revenue from presbyopia treatment increased from 56.6% in 2023 to 58.8% in 2024[51] Assets and Liabilities - Total assets decreased from HKD 1,753,598 thousand in 2023 to HKD 1,599,435 thousand in 2024, representing a decline of approximately 8.8%[9] - Non-current assets decreased from HKD 965,716 thousand in 2023 to HKD 885,835 thousand in 2024, a reduction of about 8.3%[9] - Current assets decreased from HKD 787,882 thousand in 2023 to HKD 713,600 thousand in 2024, reflecting a decline of approximately 9.4%[9] - Total liabilities decreased from HKD 588,090 thousand in 2023 to HKD 473,721 thousand in 2024, a decrease of about 19.4%[10] - Non-current liabilities decreased from HKD 417,624 thousand in 2023 to HKD 321,546 thousand in 2024, a reduction of approximately 23%[10] - Current liabilities decreased from HKD 170,466 thousand in 2023 to HKD 152,175 thousand in 2024, reflecting a decline of about 10.7%[10] - Equity attributable to owners decreased from HKD 1,134,776 thousand in 2023 to HKD 1,092,965 thousand in 2024, a decrease of approximately 3.7%[9] - Cash and cash equivalents decreased from HKD 720,216 thousand in 2023 to HKD 653,232 thousand in 2024, a decline of about 9.3%[9] Expenses and Costs - Total expenses for the year increased to HKD 625,565,000 in 2024 from HKD 540,989,000 in 2023, marking an increase of approximately 15.6%[31] - Employee benefits expenses increased to HKD 246,932,000 in 2024 from HKD 222,728,000 in 2023, representing an increase of approximately 10.9%[31] - Administrative expenses rose by 29.6% to HKD 115.7 million, driven by increases in employee benefits, consulting fees, and depreciation costs[74] - Sales expenses increased by 10.8% to approximately HKD 80.8 million, representing 11.3% of total revenue, up from 10.2% in the previous year[72] Strategic Initiatives - The company plans to open satellite clinics to support existing high-traffic locations, enhancing operational efficiency and expanding into high-potential cities[64] - The company is pursuing a merger and acquisition strategy, targeting well-known private ophthalmology clinics in Europe and potential strategic acquisitions in the Americas[65] - The group aims for a compound annual growth rate (CAGR) of 10% for revenue and EBITDA by 2028, with a focus on identifying suitable acquisition opportunities to enhance growth over the next two to three years[61] - The company anticipates announcing more acquisition deals by 2025 as part of its strategy to expand its clinic network and enhance its ophthalmic treatment capabilities[65] Shareholder Returns - The company declared an interim dividend of HKD 0.0349 per share, totaling HKD 11,570,153 for the six months ending June 30, 2024, compared to HKD 17,028,564 for the same period in 2023[50] - The company plans to propose a final dividend of HKD 0.0297 per share, totaling HKD 9,524,968 for the year ending December 31, 2024[50] - The board proposed a final dividend of HKD 0.0297 per ordinary share, totaling approximately HKD 9,524,968, pending shareholder approval[98] Financial Position - The current ratio was approximately 4.7 as of December 31, 2024, compared to 4.6 in 2023[89] - The group had cash and cash equivalents of approximately HKD 653.2 million as of December 31, 2024[88] - The group’s contingent liabilities amounted to approximately HKD 39.2 million as of December 31, 2024, down from HKD 64.4 million in 2023[82] - As of December 31, 2024, the group had outstanding borrowings of approximately HKD 0.9 million, unchanged from 2023[77] Audit and Compliance - The audit committee consists of two independent non-executive directors and one non-executive director, overseeing the group's financial reporting and risk management for the year ending December 31, 2024[92] Share Repurchase - The company repurchased a total of 300,000 shares in May 2024, representing 0.09% of the total issued shares as of the 2023 annual general meeting[93] - A total of 7,023,000 shares were repurchased under the 2024 buyback authorization, accounting for 2.1% of the total issued shares as of the 2024 annual general meeting[95] - The total cost for the shares repurchased from June to December 2024 was approximately HKD 32,103,610[95] - The company confirmed that all repurchased shares have been canceled as of the specified dates[95][100]

Financial Performance - The company reported a revenue of HKD 368,372,000 for the six months ended June 30, 2024, representing a 6.3% increase compared to HKD 346,382,000 in 2023[5]. - Adjusted gross profit for the same period was HKD 158,146,000, down 6.8% from HKD 169,739,000 in 2023[5]. - Adjusted net profit after tax was HKD 62,285,000, reflecting an 11.6% decrease from HKD 70,483,000 in 2023[5][6]. - The company experienced a significant decline in adjusted EBITDA, which was HKD 46,309,000, a 32.0% decrease compared to HKD 68,111,000 in 2023[5]. - The adjusted net profit margin for the period was approximately 16.9%, down from 20.3% in the previous year[5]. - The company reported a total revenue of HKD 148,013 thousand for the six months ended June 30, 2024, compared to HKD 167,582 thousand in the previous year, reflecting a decline of 11.7%[8]. - The company reported a net profit of HKD 44,154,000 for the six months ended June 30, 2024, compared to a profit of HKD 46,309,000 for the same period in 2023, reflecting a decrease of approximately 4.9%[20]. - The company reported a total comprehensive income of HKD 32,341 for the period, down from HKD 102,201 in the previous year[18]. - The company reported a foreign exchange loss related to global offering proceeds of HKD 323 thousand, compared to a gain of HKD 288 thousand in the previous year[8]. - The company reported a total of HKD 918,397 in non-current assets as of June 30, 2024, compared to HKD 930,878 as of December 31, 2023[47]. Market Expansion and Strategy - The company plans to expand its market presence and invest in new clinic openings to drive future growth[5]. - EuroEyes is focusing on enhancing its product offerings and technology development to improve operational efficiency[5]. - The company has incurred pre-opening expenses related to new clinics, impacting its short-term profitability[6]. - The company plans to open a new clinic in Kiel, Germany, by the end of this year, and satellite clinics in Beijing and Shanghai, enhancing its market presence in high-potential cities[100]. - The company expects three new clinics in Germany and Hong Kong to reach breakeven by the end of 2024 and 2025, contributing to EBITDA and net profit growth from 2025 onwards[99]. - The company is actively pursuing mergers and acquisitions, targeting renowned private ophthalmology clinics in Europe and Asia, with a focus on emerging markets[101]. Financial Management and Risks - EuroEyes aims to mitigate foreign exchange losses associated with global offerings through strategic financial management[6]. - The management emphasizes the importance of non-IFRS financial metrics for evaluating business performance and trends[7]. - The company maintains a cautious liquidity risk management strategy, ensuring sufficient cash and credit facilities to meet funding needs[28]. - The company's credit risk remains low, with expected credit losses based on IFRS 9 being minimal[27]. - The company has not made any significant changes to its risk management policies since year-end[26]. Employee and Operational Expenses - Total employee benefit expenses increased to HKD 123,470,000 from HKD 103,915,000, reflecting a growth of 18.7% year-over-year[56]. - The company's operating expenses increased due to employee benefits and depreciation of property, plant, and equipment, with employee benefits rising by 21.8% to HKD 21.8 million[109]. - Administrative expenses for the six months ended June 30, 2024, were approximately HKD 48.7 million, a 26.5% increase from the same period in 2023, accounting for 13.2% of total revenue[108]. Shareholder Information - The company declared an interim dividend of HKD 0.0349 per share, totaling approximately HKD 11,619,606, a decrease from HKD 17,028,564 in the same period last year[118]. - The total issued share capital as of June 30, 2024, is 332,940,000 shares[122]. - The company repurchased shares amounting to HKD 5,819,000 during the period, compared to no repurchases in the same period last year[21]. - The company repurchased a total of 1,417,000 shares, representing 0.43% of the total issued shares as of the 2024 Annual General Meeting[135]. Revenue Breakdown by Segment - The company has identified five reportable segments: Germany, China, Denmark, and the UK, with Germany contributing the highest revenue of HKD 206,318,000 for the six months ended June 30, 2024[37]. - Revenue from vision correction services reached HKD 364,492 for the six months ended June 30, 2024, representing an increase of 6.3% compared to HKD 342,952 for the same period in 2023[48]. - Revenue from Germany increased by 9.9% to HKD 201.1 million, representing 54.6% of total revenue[94]. - In China, revenue grew by 3.9% to HKD 75.6 million, despite macroeconomic challenges, with lens replacement surgeries achieving a 27.9% increase[94]. - The UK revenue rose by 21.1% to HKD 57.9 million, benefiting from the new flagship clinic in Knightsbridge[95]. Cash Flow and Liquidity - Cash generated from operating activities was HKD 102,999,000, an increase of 11.7% compared to HKD 92,282,000 in the same period last year[21]. - The company incurred a net cash outflow from investing activities of HKD 53,243,000, an improvement from HKD 63,987,000 in the prior year[21]. - The cash and cash equivalents at the end of the period stood at HKD 689,561,000, down from HKD 781,630,000 at the end of June 2023, representing a decrease of approximately 11.8%[21]. Future Outlook - The company maintains a cautious outlook for the remainder of 2024 due to macroeconomic uncertainties but is optimistic about its growth pillars supporting performance through 2026[98]. - The expected revenue growth rate for Vision Clinic Partners is projected to be between 10% and 14% for 2024, compared to 5% to 10% for 2023[33].